Escitalopram and Terminal state - a phase IV clinical study of FDA data

Summary:

Terminal state is reported as a side effect among people who take Escitalopram (escitalopram oxalate), especially for people who are female, 60+ old, also take Aspirin, and have Primary myelofibrosis.

The phase IV clinical study analyzes which people have Terminal state when taking Escitalopram. It is created by eHealthMe based on reports of 75,134 people who have side effects when taking Escitalopram from the FDA, and is updated regularly.

What is Escitalopram?

Escitalopram has active ingredients of escitalopram oxalate. It is often used in depression. eHealthMe is studying from 78,082 Escitalopram users. Check the latest studies of Escitalopram.

What is Terminal state?

Terminal state (the transitional states between life and biological death) is found to be associated with 370 drugs and 563 conditions by eHealthMe. Check the latest studies of Terminal state.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 30, 2026

75,134 people reported to have side effects when taking Escitalopram.
Among them, 25 people (0.03%) have Terminal state.

Could Escitalopram cause Terminal state?

Among these 25 people:

What is the gender of people who have Terminal state when taking Escitalopram? *

female: 75 %
male: 25 %

What is the age of people who have Terminal state when taking Escitalopram? *

What are other drugs people take besides Escitalopram? *

What are other side effects people have besides Terminal state? *

Fall: 16 people, 64.00%
Gait Disturbance: 15 people, 60.00%
Dizziness: 15 people, 60.00%
Weight Decreased: 14 people, 56.00%
Nausea And Vomiting: 14 people, 56.00%
Weakness: 14 people, 56.00%
Urinary Tract Infection: 13 people, 52.00%
Thrombocytopenia (decrease of platelets in blood): 13 people, 52.00%
Splenomegaly (enlargement of spleen): 13 people, 52.00%
Dyspnea (difficult or laboured breathing): 13 people, 52.00%

What are the existing conditions these people have? *

Primary Myelofibrosis (primary disorder of the bone marrow): 13 people, 52.00%
Bone Pain: 10 people, 40.00%
Polycythaemia Vera (blood disorder in which the bone marrow makes too many red blood cells): 9 people, 36.00%
Pain: 4 people, 16.00%
Urinary Tract Infection: 3 people, 12.00%
Parkinson's Disease: 3 people, 12.00%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 3 people, 12.00%
Muscle Spasms (muscle contraction): 2 people, 8.00%
Confusional Arousal (behaviours that occur around sleep): 2 people, 8.00%
Crohn's Disease (a condition that causes inflammation of the gastrointestinal tract): 2 people, 8.00%

* Approximation only. Some reports may have incomplete information.

Do you take Escitalopram and have Terminal state?

- Check whether Terminal state is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Escitalopram:

Escitalopram (78,082 reports)

Terminal state treatments and more:

Terminal state (7,004 reports)

Browse all side effects of Escitalopram:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Terminal state:

Terminal state (370 drugs)

Browse all the conditions that are associated with Terminal state:

Terminal state (563 conditions)

Related publications that referenced our studies

O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .
O’Brien FE, O’Connor RM, Clarke G, Donovan MD, Dinan TG, Griffin BT, Cryan JF, "The P-glycoprotein inhibitor cyclosporin A differentially influences behavioural and neurochemical responses to the antidepressant escitalopram", Behavioural brain research, 2014 Mar .

How the study uses the data?

The study uses data from the FDA. It is based on escitalopram oxalate (the active ingredients of Escitalopram) and Escitalopram (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.